OBJECTIVE -Children of affected probands are at increased risk for type 1 diabetes. The objective of this study was to determine and stratify the risk for islet autoimmunity and childhood diabetes in newborn offspring of affected parents using family history and HLA genetic markers.
T ype 1 diabetes is preceded by autoimmunity against the insulinproducing islet ␤-cells (1, 2) . The development of islet autoantibodies and type 1 diabetes is influenced by both genetic and environmental factors, and the detection of islet autoantibodies in members of affected families identifies a minority of individuals who have a markedly elevated risk of type 1 diabetes (3). On this principle, two large-scale intervention trials to delay onset of type 1 diabetes in islet autoantibody-positive first-degree relatives of patients with type 1 diabetes have recently been completed in North America and Europe (4, 5) . Despite promising pilot studies, both trials reported no delay in onset of type 1 diabetes in the treatment group. Successful prevention may, therefore, require alternative therapies and/or strategies that treat diabetes very early in the autoimmune process or before its appearance.
Primary prevention requires an ability to identify children who will develop autoimmunity. The German BABYDIAB study prospectively followed islet autoantibody and diabetes development in newborn offspring of parents with type 1 diabetes with the prospect of designing early intervention trials (6) . The risk of developing islet autoantibodies in BABY-DIAB children is strongly linked to HLA genes (7) . Nevertheless, several children developed multiple antibodies and diabetes in the absence of established type 1 diabetes genetic markers, implying the presence of other strong familial genetic or environmental risk factors. In this study, we asked whether the extent of the family history contributed to the risk of developing islet autoantibodies and type 1 diabetes beyond that conferred by the locus of type 1 diabetes (IDDM1). The findings indicate that combining family history risk with known type 1 diabetes risk genes significantly improves our ability to predict the development of diabetes-associated autoantibodies in the neonate and to implement primary prevention trials in first-degree relatives of patients with type 1 diabetes.
RESEARCH DESIGN AND
METHODS -BABYDIAB prospectively follows offspring of mothers and/or fathers with type 1 diabetes from birth. Venous blood sampling and collection of questionnaire data were performed at birth (cord blood) as well as at ages 9 months, 2 years, 5 years, 8 years, and 11 years (6 -8) . Recruitment into the study began in 1989 and ended in 2000. Offspring fulfilled entry criteria if they were recruited at birth and participated in the 9-month follow-up. A total of 1,610 offspring fulfilled these criteria, including 1,002 newborns of mothers with type 1 diabetes, 580 newborns of fathers with
type 1 diabetes, and 28 newborns of two parents with type 1 diabetes. Islet autoantibodies were measured in samples from all scheduled visits and yearly after developing islet autoantibodies. Children were prospectively monitored for the development of diabetes. Monitoring in autoantibody-positive children was performed by oral glucose tolerance test (OGTT) every 6 -12 months and/or monthly random blood glucose values. HLA DR and DQ genotypes were determined in 1,398 offspring, and the remaining 212 children did not provide a suitable sample for HLA typing. The median follow-up time from birth to last sample was 6.5 years (range 0.7-12.3) and from birth to last contact was 6.8 years (1.3-13.3). Offspring were followed for a total of 9,480 subject-years for islet autoantibodies and for 12,190 subject-years for development of type 1 diabetes. All families gave written informed consent to participate in the BABYDIAB study. The study was approved by the ethical committee of Bavaria, Germany (Bayerische Landesärztekammer No. 95357).
Autoantibodies
Insulin autoantibody (IAA), GAD antibody (GADA), and tyrosine phosphatase IA2 antibody (IA2A) were determined by radiobinding assays as described previously (6, 9) . The upper limits of normal corresponded to the 99th percentile of the control subjects and were 8.5 local units/ml or 25 World Health Organization (WHO) units/ml for GADA, 2.5 local units/ml or 4 WHO units/ml for IA2A, and 1.5 local units/ml for IAA (6, 8) . Using these thresholds for positivity, the assays had sensitivities and specificities of 84 and 96% (GADA), 66 and 100% (IA2A), 64 and 99% (IAA), and 78 and 100%, respectively, for multiple islet autoantibodies in the Third Diabetes Autoantib o d i e s S t a n d a r d i z a t i o n P r o g r a m Proficiency Workshop. The interassay coefficient of variation for samples with low autoantibody titer was 11% for IAA, 18% for GADA, and 16% for IA2A. All measurements were performed on coded samples that were operator blinded.
IDDM1/HLA
HLA-DRB1, HLA-DQA1, and HLA-DQB1 alleles were typed using PCRamplified DNA and nonradioactive sequence-specific oligonucleotide probes as described previously (7, 10) .
Family history of type 1 diabetes
At birth and at each follow-up visit, parents recorded which members in the family had type 1 diabetes, which for this purpose was defined as onset before 35 years of age and requiring insulin therapy.
Outcome definition
Outcome markers used in the study were the appearance of islet autoantibodies and the development of diabetes. Offspring were considered islet autoantibody positive if at least two samples after birth were found to contain one or more islet autoantibodies (IAA, GADA, or IA2A). Offspring who were found to have autoantibodies in only one follow-up sample were classified as islet autoantibody negative. Offspring with confirmed positive islet autoantibodies were subsequently classified as either single (only one autoantibody) or multiple (at least two autoantibodies) antibody positive. Diabetes was diagnosed according to WHO criteria (11) . Diabetes was diagnosed by OGTT monitoring as part of the study protocol in 5 children and by random blood glucose measurements performed by families or pediatricians followed by OGTT or fasting blood glucose measurements in 19 children.
Statistical analysis
The cumulative frequencies of islet autoantibodies and type 1 diabetes were determined using life table analysis with follow-up calculated from birth until the age of the first positive sample or last negative sample as described previously (6). Cox's proportional hazards model was used to determine how the development of diabetes-associated islet autoantibodies and diabetes may be predicted in the neonate. Family history variables examined by univariate analysis in the model were the number of the child's parents or siblings with type 1 diabetes and whether the child's parents had a first-degree relative (mother, father, sister, or brother) with type 1 diabetes. Follow-up was calculated from birth until the age of the first positive sample for islet autoantibodies and from birth to the age at onset of diabetes or last contact for diabetes. Variables that were significantly associated with islet autoantibody risk (P Ͻ 0.05) were included in a multivariate analysis by Cox's proportional hazards model with forward conditional stepwise regression. The variable HLA genotype was also included in the multivariate analysis. HLA genotype was categorized according to previously de- fined diabetes risk in this study cohort (7) as high-risk DR4 (HLA DRB1*03/ DRB1*04-DQB1*0302 or DRB1*04-DQB1*0302/DRB1*04-DQB1*0302), m o d e r a t e -r i s k D R 4 ( D R 4 -D Q 8 / DRB1*08-DQA1*0401-DQB1*0402, DR4-DQ8/DRB1*13-DQA1*0102-DQB1*0604, DR4-DQ8/DRB1*01-DQA1*01-DQB1*0501), or other genotypes (7) . For all analyses, a two-tailed P value of 0.05 was considered significant. All statistical analyses were performed using the Statistical Package for Social Science (SPSS version 11.0, Chicago, IL).
RESULTS

Islet autoantibodies in BABYDIAB offspring
A total of 85 offspring developed islet autoantibodies during follow-up, 51 of which developed multiple islet autoantibodies (median age at first antibodypositive sample, 1.8 years Table 1) . The risk of type 1 diabetes was significantly increased in offspring who had both parents with type 1 diabetes (10.9% by 5 years of age) and in offspring who had a parent and sibling with type 1 diabetes (11.8% by 5 years of age) compared with offspring with just one parent with type 1 diabetes (0.8% by 5 years of age; both P Ͻ 0.0001). The risk of developing single islet autoantibodies was not associated with multiple family history of type 1 diabetes and did not differ between offspring of mothers with type 1 diabetes and offspring of fathers with type 1 diabetes (data not shown).
Family history and genetic determinants of islet autoantibody and diabetes risk in offspring-multivariate analysis Multiple family history was included in a multivariate analysis using Cox's proportional hazard model together with IDDM1 (HLA) genotype (Table 2) . Sequential addition of the variables using conditional stepwise regression showed that both HLA genotypes and a multiple family history of type 1 diabetes significantly contributed to the risk for multiple islet ). An increased risk of type 1 diabetes was associated with high-risk HLA genotypes (10.9; P Ͻ 0.0001), moderate-risk DR4 genotypes (4.3; P ϭ 0.03), and a multiple first-degree family history of type 1 diabetes in the child (7.8; P Ͻ 0.0001).
Combining risk factors to identify neonates with high risk of type 1 diabetes Multivariate analysis indicated that adding risk factors may help stratify risk. The ability to identify neonates who would develop islet autoantibodies or diabetes using both IDDM1 (HLA) and a multiple first-degree family history in the child was therefore examined. After excluding 212 offspring because of a missing HLA genotype, at least one of these risk factors was identified in 303 of 1,398 children, including 40 of 51 children (78%) in whom multiple antibodies developed and 20 of 23 children (87%) in whom type 1 diabetes developed (Table 3) . Four of the children who developed multiple antibodies and three of the children who developed diabetes had a multiple family history risk but no HLA risk genotype. The risk of developing multiple islet autoantibodies in children with one or more risk factor was 14.2% (10 -18.4) by 5 years of age, compared with 1% (0.4 -1.6) in children with no risk factors (P Ͻ 0.0001). The risk of developing multiple islet autoantibodies and type 1 diabetes was incremental with the number of risk factors present (Table 3 and Fig. 1 CONCLUSIONS -Y o u n g -o n s e t type 1 diabetes is increasing in frequency in most western countries, particularly in children younger than 5 years (12) (13) (14) .
Children who have a first-degree relative with type 1 diabetes are at highest risk (2) . Affected families, therefore, are targeted for counseling and for investigative studies to identify etiologic factors of type 1 diabetes and to test intervention therapies (4, 5, 8, (15) (16) (17) (18) (19) (20) (21) (22) . The German BABYDIAB study was designed to determine and stratify the risk for islet autoimmunity and type 1 diabetes in offspring of parents with type 1 diabetes.
Having previously established that risk of diabetes was associated with the development of multiple islet autoantibodies at an early age (6), we asked whether development of multiple islet autoantibodies and diabetes could be predicted soon after birth. An ability to predict in which individuals multiple antibodies would develop could facilitate the design of targeted primary prevention such as the Trial to Reduce Type 1 Diabetes in the Genetically at Risk (23) or intensive follow-up studies such as The The BABYDIAB study has shown that the likelihood of developing diabetesrelevant autoantibodies can be predicted using genetic markers in the neonate. A limitation of the study is that it only includes offspring of affected parents, and we cannot assume that the findings will be true in high-risk newborns of unaffected parents. In relatives, combining multiple type 1 diabetes family history and IDDM1 (HLA) genotype could classify newborns into groups with multiple islet autoantibody risk ranging from 1 to almost 50% and with diabetes risk ranging from 0 to 20% by 5 years of age. Using this model, Ͼ75% of the children had a risk that was comparable to that of children in unaffected families and 1% of children had a risk approaching that in identical twins of type 1 diabetes patients. Neonates with the highest risk could be targeted for intensive prospective study to identify environment-gene interactions and could be candidates for prophylactic primary prevention therapy. 
